RWF_WO29522

A PHASE III, MULTICENTER, RANDOMIZED,PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER

This study is being conducted to determine the efficacy and safety in using Atezolizumab (MPDL3280A) in combination with nab-paclitaxel in treating patients with metastatic breast cancer. The safety of single-agent nab-paclitaxel has been determined in previous studies of patients with metastatic breast cancer, and preliminary data shows the use of Atezolizumab (MPDL3280A) is safe to use in combination with chemotherapy.

Inclusion Criteria:

* Metastatic or locally advanced, histologically documented Triple-Negative Breast Cancer (TNBC)

* No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC



Phase III
NCT02425891
Oncology
Breast
Alison Conlin, M.D.
Genentech
Nikki Moxon
  • Oncology and Hematology Care Eastside